Capstone Therapeutics (CAPS) Announces A Lipimetix Development, LLC Presentation At The American Heart Association Scientific Sessions: Pre-Clinical Data Demonstrating Significant Post Treatment Benefit Of AEM-28 On Established Atherosclerotic Lesions
11/19/2013 9:18:34 AM
TEMPE, Ariz. and BOSTON, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Capstone Therapeutics' (OTCQB:CAPS) joint venture, LipimetiX Development, LLC, today announced the presentation of pre-clinical data demonstrating the sustained benefit effect of their apolipoprotein E mimetic peptide (AEM-28) on established atherosclerotic lesions in Apo E null mice at the American Heart Association Scientific Sessions meeting, November 16 – 20, 2013, in Dallas, TX.
Help employers find you! Check out all the jobs and post your resume.
comments powered by